<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03838328</url>
  </required_header>
  <id_info>
    <org_study_id>Dose effect of TA on DVT</org_study_id>
    <nct_id>NCT03838328</nct_id>
  </id_info>
  <brief_title>Dose Effect of Tranexamic Acid on the Incidence of Deep Venous Thrombus in Cardiac Surgery</brief_title>
  <official_title>Dose Effect of Tranexamic Acid on the Incidence of Deep Venous Thrombus in Cardiac Surgery With Cardiopulmonary Bypass</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SHI Jia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences, Fuwai Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In recent years, the lysine analogs tranexamic acid (TXA) has gained wide use in cardiac
      surgery as a blood-sparing agent. However, the safety of the drug and its impact on overall
      outcomes of cardiac surgery remains debated. The current study evaluates the dose effect of
      TXA on the incidence of deep venous thrombus (DVT) in cardiac surgery with cardiopulmonary
      bypass. Also, the dose effect of TXA on bleeding and allogeneic transfusion is evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The allocation is masked for the participant, care provider, investigator and outcomes assessor.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of deep venous thrombosis</measure>
    <time_frame>Within 7 days postoperatively</time_frame>
    <description>Defined as the incidence of new-onset deep venous thrombosis postoperatively diagnosed by ultrasound</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rate of new-onset thrombotic events</measure>
    <time_frame>Within 90 days postoperatively</time_frame>
    <description>Thrombotic events include ischemic stroke, renal failure, myocardial infarction and pulmonary embolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of allogeneic RBC transfusion</measure>
    <time_frame>Within 30 days postoperatively</time_frame>
    <description>Allogeneic blood product includes packed red blood cell</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The volume of allogeneic RBC transfusion</measure>
    <time_frame>Within 30 days postoperatively</time_frame>
    <description>Allogeneic blood product includes packed red blood cell</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in ICU and hospital</measure>
    <time_frame>Within 90 days postoperatively</time_frame>
    <description>The time interval between the end of the operation and the discharge from ICU or the hospital.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Thromboses, Deep Vein</condition>
  <condition>Tranexamic Acid Adverse Reaction</condition>
  <arm_group>
    <arm_group_label>Dose group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose regimen of tranexamic acid in group 1 includes a loading dose of 30mg/kg before skin incision and a maintenance dose of 20mg/kg/hr until the end of the operation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose regimen of tranexamic acid in group 2 includes a loading dose of 20mg/kg before skin incision and a maintenance dose of 15mg/kg/hr until the end of the operation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose group 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The dose regimen of tranexamic acid in group 3 includes a loading dose of 10mg/kg before skin incision and a maintenance dose of 10mg/kg/hr until the end of the operation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>Tranexamic acid will be delivered by loading dose plus maintenance infusion until the end of the operation.</description>
    <arm_group_label>Dose group 1</arm_group_label>
    <arm_group_label>Dose group 2</arm_group_label>
    <arm_group_label>Dose group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients receiving selective cardiac surgery with cardiopulmonary bypass due to
             coronary, valvular or congenital heart disease

          -  Written consent obtained

        Exclusion Criteria:

          -  Allergy or contraindication to tranexamic acid

          -  Severe renal impairment (serum creatinine &gt;250 μmol/l, or estimated creatinine
             clearance &lt;25 ml/min)

          -  Thromboembolic disease including but not limited to: history of pulmonary embolism,
             spontaneous arterial thrombosis or familial hypercoaguability (eg. Lupus
             anticoagulant, protein C deficiency)

          -  Thrombocytopenia defined as a platelet count &lt;100,000/ml

          -  Coagulopathy defined as an international normalized ratio &gt; 1.5 prior to surgery

          -  Currently enrolled in another perioperative interventional study

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jia Shi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fuwai Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jia Shi, M.D.</last_name>
    <phone>86 10 88322467</phone>
    <email>shiandypumc@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chinese Academy of Medical Sciences， Fuwai Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 1, 2019</study_first_submitted>
  <study_first_submitted_qc>February 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2019</study_first_posted>
  <last_update_submitted>February 9, 2019</last_update_submitted>
  <last_update_submitted_qc>February 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences, Fuwai Hospital</investigator_affiliation>
    <investigator_full_name>SHI Jia</investigator_full_name>
    <investigator_title>Associate Professor and Vice Chair of the Anesthesiology Department</investigator_title>
  </responsible_party>
  <keyword>dose effect</keyword>
  <keyword>tranexamic acid</keyword>
  <keyword>deep vein thromboses</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

